These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21347793)

  • 1. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
    Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
    Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
    Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
    Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.
    Tsai WC; Lee MY; Chen FL; Wang PH; Lin WL; Ruan A; Li YJ; Wang SC; Chiang H; Han CP
    Arch Gynecol Obstet; 2011 Sep; 284(3):721-9. PubMed ID: 21046136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
    Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
    Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
    Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
    Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
    Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
    J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
    Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
    Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.